BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/18/2016 9:50:00 AM | Browse: 813 | Download: 1313
 |
Received |
|
2015-08-29 16:30 |
 |
Peer-Review Started |
|
2015-09-07 10:06 |
 |
To Make the First Decision |
|
2015-10-08 16:18 |
 |
Return for Revision |
|
2015-10-19 00:39 |
 |
Revised |
|
2015-11-11 00:50 |
 |
Second Decision |
|
2016-01-14 17:51 |
 |
Accepted by Journal Editor-in-Chief |
|
2016-01-15 01:52 |
 |
Accepted by Executive Editor-in-Chief |
|
2016-03-09 12:33 |
 |
Articles in Press |
|
2016-03-09 12:33 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-03-14 09:24 |
 |
Publish the Manuscript Online |
|
2016-03-18 09:50 |
ISSN |
2222-0682 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Review |
Article Title |
Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Crystal C Lipsey, Adriana Harbuzariu, Danielle Daley-Brown and Ruben R Gonzalez-Perez |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
The National Cancer Institute at the National Institutes of Health |
1R41 CA183399-01A1 |
The National Cancer Institute at the National Institutes of Health |
5U54 CA118638 |
Congressionally Directed Medical Research Programs-Department of Defense |
W81XWH-13-1-0382 (to Gonzalez-Perez RR) |
NCI |
S21 MD000101 |
NCI |
5G12 MD0076021 |
NCI |
G12 RR026250-03 |
NIH |
1C06 RR18386 (to Morehouse School of Medicine) |
NIH |
1C06 RR18386 (to Morehouse School of Medicine) |
NIH |
5T32HL103104-04 (to Daley-Brown D) |
|
Corresponding Author |
Ruben R Gonzalez-Perez, PhD, Department of Microbiology, Biochemistry and Immunology, Graduate Education in Biomedical Sciences, Morehouse School of Medicine, 720 Westview Drive, Hugh Gloster Suite 329, Atlanta, GA 30310, United States. rgonzalez@msm.edu
|
Key Words |
Obesity; Leptin; Breast cancer; Endometrial cancer; Pancreatic cancer; Notch; interleukin-1 and leptin crosstalk outcome |
Core Tip |
Obesity is a global pandemic and a risk factor for a number of cancers. Obesity is characterized by high levels of body fat (adiposity) and leptin. Research shows that leptin and its oncogenic crosstalk Notch, interleukin-1 and leptin crosstalk outcome (NILCO) provide insight on the link between obesity and cancer progression. Thus, leptin and NILCO can act as mito-genic, inflammatory, and angiogenic cues promoting the progression of cancer, cancer stem cells, and drug resistance. This review shows updated information on leptin and NILCO’s oncogenic roles in breast, endometrial, and pancreatic cancers.
|
Publish Date |
2016-03-18 09:50 |
Citation |
Lipsey CC, Harbuzariu A, Daley-Brown D, Gonzalez-Perez RR. Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer. World J Methodol 2016; 6(1): 43-55 |
URL |
http://www.wjgnet.com/2222-0682/full/v6/i1/43.htm |
DOI |
http://dx.doi.org/10.5662/wjm.v6.i1.43 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345